Form 4: Catalyst Pharmaceuticals Executive Sells Shares on Open Market

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, sold 7,541 shares of common stock at $16.07 per share on June 7, 2024.

Summary

• Jeffrey Del Carmen, the Chief Commercial Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported a transaction involving the sale of company stock.
• On June 7, 2024, Del Carmen sold 7,541 shares of common stock at a price of $16.07 per share.
• Following the transaction, Del Carmen directly owns 18,427 shares of Catalyst Pharmaceuticals.
• The sale was executed on the open market for personal reasons and not due to any disagreement with the company.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a stock sale by an executive. The provided reason suggests no negative implications for the company.

Management Comments

• The shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

Industry Context

Executive stock sales are a common occurrence and are often scrutinized by investors to gauge insider sentiment about the company's prospects. It's important to consider the context of the sale, such as the executive's personal financial situation and the overall market conditions.

Stakeholder Impact

• The stock sale could potentially influence shareholder perception of the company, although the stated reason for the sale mitigates potential negative interpretations.

Key Dates